No abstract

No abstract

No abstract

Recent studies in our laboratory have shown that in some teleosts, 3,5-di-iodothyronine (T 2 or 3,5-T 2 ) is as bioactive as 3,5,3 0 -tri-iodothyronine (T 3 ) and that its effects are in part mediated by a TRb1 (THRB) isoform that contains a 9-amino acid insert in its ligand-binding domain (long TRb1 (L-TRb1)), whereas T 3 binds preferentially to a short TRb1 (S-TRb1) isoform that lacks this insert. To further understand the functional relevance of T 2 bioactivity and its mechanism of action, we used in vivo and ex vivo (organotypic liver cultures) approaches and analyzed whether T 3 and T 2 differentially regulate the S-TRb1 and L-TRb1s during a physiological demand such as growth. In vivo, T 3 and T 2 treatment induced body weight gain in tilapia. The expression of L-TRb1 and S-TRb1 was specifically regulated by T 2 and T 3 respectively both in vivo and ex vivo. The TR antagonist 1-850 effectively blocked thyroid hormone-dependent gene expression; however, T 3 or T 2 reversed 1-850 effects only on S-TRb1 or L-TRb1 expression, respectively. Together, our results support the notion that both T 3 and T 2 participate in the growth process; however, their effects are mediated by different, specific TRb1 isoforms.

Anneroth G, Batsakis JG, Luna M: Malignancy grading of squamous cell carcinoma in the floor of mouth related to clinical evaluaition. Scand J Dent Res 1986; 94: 347-58.Abstract -A multifactorial grading system -was used for histologic classification and grading of malignancy in 89 patients with squamous cell carcinoma in the floor of the mouth. All patients had been treated with surgery alotie and only those patients were included in the study who at the initial diagnosis had no clinically suspected regional lynaph node or distant metastatic involvement. There was a statistically significant correlation between the tnean total malignancy scoring, on the one hand, and clinical staging, frequency of recurrences, and death from the first primary oral carcinoma, on the other.